Our goal is early-disease detection.
Breathe BioMedical will make early disease screening of cancer and other diseases through breath analysis the new standard for routine screening.
Our technology works by identifying the biomarkers of disease. We have active studies in lung cancer and breast cancer and are actively planning future studies. This technology will revolutionize multi-disease screening.
Our pursuit is to make our simple breath test available in physician offices, clinics and pharmacies. In a single test we will screen for numerous diseases.
Our Mission: To empower people with a simple breath test that provides early detection of cancer and other diseases.
Our Vision: A non-invasive screening test to save lives.
Our Focus: To improve existing lung cancer screening programs through the commercialization of our proven lung cancer detection method.
Just breathe®
OUR RESULTS
In 2020, we worked with the University of New Brunswick (UNB) to publish a breath biomarker poster on the identification of lung cancer biomarkers at the breath biopsy conference. This same year, we worked with the American Society of Clinical Oncology (ASCO) to publish an abstract on the use of IR absorption measurements for the detection of non-small cell lung cancer at the ASCO conference.
OUR PARTNERS
Breathe BioMedical has an amazing team of partners who conduct research with our technology and support our goals.
THE WHITE RIBBON PROJECT
Breathe BioMedical is a proud supporter of The White Ribbon Project.
ISO 13485 Certified
ISO 13485 Certified is an international standard for quality systems for medical device manufacturers across the globe. This certification demonstrates, by third party review, that Breathe BioMedical’s full end-to-end quality management system meets the highest standard for safety and quality.
